A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?

医学 临床试验 内科学 肿瘤科 临床终点 人口 耐火材料(行星科学) 外科 天体生物学 环境卫生 物理
作者
Roelof van Ewijk,Morgane Cleirec,Nikolas Herold,Marie-Cécile Le Deley,Natasha van Eijkelenburg,Pascaline Boudou‐Rouquette,Severine Risbourg,Sandra J. Strauss,Emanuela Palmerini,Kjetil Boye,Leo Kager,Stefanie Hecker‐Nolting,Antonin Marchais,Nathalie Gaspar
出处
期刊:Cancer Treatment Reviews [Elsevier BV]
卷期号:120: 102625-102625
标识
DOI:10.1016/j.ctrv.2023.102625
摘要

Background/ObjectiveTo analyze changes in recurrent/refractory osteosarcoma phase II trials over time to inform future trials in this population with poor prognosis.MethodsA systematic review of trials registered on trial registries between 01/01/2017–14/02/2022. Comparison of 98 trials identified between 2003 and 2016. Publication search/analysis for both periods, last update on 01/12/2022.ResultsBetween 2017 and 2022, 71 phase-II trials met our selection criteria (19 osteosarcoma-specific trials, 14 solid tumor trials with and 38 trials without an osteosarcoma-specific stratum). The trial number increased over time: 13.9 versus 7 trials/year (p = 0.06). Monotherapy remained the predominant treatment (62% vs. 62%, p = 1). Targeted therapies were increasingly evaluated (66% vs. 41%, P = 0.001). Heterogeneity persisted in the trial characteristics. The inclusion criteria were measurable disease (75%), evaluable disease (14%), and surgical remission (11%). 82% of the trials included pediatric or adolescent patients. Biomarker-driven trials accounted for 25% of the total trials. The survival endpoint use (rather than response) slightly increased (40% versus 31%), but the study H1/H0 hypotheses remained heterogeneous. Single-arm designs predominated over multiarm trials (n = 7). Available efficacy data on 1361 osteosarcoma patients in 58 trials remained disappointing, even though 21% of these trials were considered positive, predominantly those evaluating multi-targeted kinase inhibitors.ConclusionDespite observed changes in trial design and an increased number of trials investigating new therapies, high heterogeneity remained with respect to patient selection, study design, primary endpoints, and statistical hypotheses in recently registered phase II trials for osteosarcoma. Continued optimization of trial design informed by a deeper biological understanding should strengthen the development of new therapies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星辰大海应助guard采纳,获得10
刚刚
怕孤独的云朵完成签到,获得积分10
1秒前
852应助西门子云采纳,获得10
1秒前
1秒前
薄荷加冰完成签到,获得积分10
1秒前
Stone完成签到,获得积分20
1秒前
orixero应助洁净的士晋采纳,获得10
2秒前
2秒前
丘比特应助Gilana采纳,获得10
2秒前
繁荣的豁给繁荣的豁的求助进行了留言
2秒前
慕青应助曲奇饼干采纳,获得10
3秒前
3秒前
ccc完成签到,获得积分10
3秒前
3秒前
饕邪完成签到,获得积分10
4秒前
飞雪完成签到,获得积分10
4秒前
今天也不想搬砖完成签到,获得积分10
4秒前
无私追命发布了新的文献求助10
5秒前
天天快乐应助zdz采纳,获得10
5秒前
ludong_0应助Ma采纳,获得10
5秒前
顾矜应助旦丁洋采纳,获得10
5秒前
sciscisci发布了新的文献求助10
5秒前
股价发布了新的文献求助10
5秒前
5秒前
qiqi发布了新的文献求助10
6秒前
缥缈傥发布了新的文献求助10
6秒前
6秒前
6秒前
6秒前
6秒前
慕青应助认真代曼采纳,获得10
6秒前
老迟到的金鱼应助Rose采纳,获得20
7秒前
7秒前
天天快乐应助可靠的海豚采纳,获得10
8秒前
yhdeng完成签到,获得积分10
9秒前
dongdong发布了新的文献求助10
9秒前
风中的碧空完成签到,获得积分10
9秒前
LLL发布了新的文献求助10
9秒前
量子星尘发布了新的文献求助30
10秒前
10秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974463
求助须知:如何正确求助?哪些是违规求助? 3518823
关于积分的说明 11196212
捐赠科研通 3255008
什么是DOI,文献DOI怎么找? 1797655
邀请新用户注册赠送积分活动 877052
科研通“疑难数据库(出版商)”最低求助积分说明 806130